Theravance Biopharma is a biopharmaceutical company whose commercial focus includes YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of COPD in the U.S. The product is partnered for commercialization, with economics tied to U.S. profit-sharing and royalties rather than a large owned sales force alone. The company concentrates on respiratory medicine and related partnered assets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 26.2 | — | 54.8 | — |
| Q3 2025 | 20 | — | 3.6 | — |
| Q4 2025 | 45.9 | — | 61 | — |
| Q1 2026 | 17.7 | — | -4.9 | — |
| Q2 2026 | 20.7 | -20.9% | -5.9 | -110.8% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Beta Bionics, Inc. (BBNX), First Financial Corporation (THFF), Astec Industries, Inc. (ASTE), Daktronics, Inc. (DAKT), SI-BONE, Inc. (SIBN), Navient Corporation (NAVI)